BioCentury | Aug 20, 2012
Finance

Converts finding faith in biotech

Convertible debt investors are hungry for paper and biotechs are eager to capitalize on this - even those without marketed products and substantial revenues. Over the last decade, biotechs with sizable and growing revenues have primarily...
BioCentury | Sep 6, 2004
Strategy

Back to School 2004: Asset accumulation

A few months ago, BioCentury spilled a lot of ink to deconstruct the NRDO model of no-research, development only companies being formed to scavenge for products or technologies that can be commercialized quickly and offer...
Items per page:
1 - 2 of 2
BioCentury | Aug 20, 2012
Finance

Converts finding faith in biotech

Convertible debt investors are hungry for paper and biotechs are eager to capitalize on this - even those without marketed products and substantial revenues. Over the last decade, biotechs with sizable and growing revenues have primarily...
BioCentury | Sep 6, 2004
Strategy

Back to School 2004: Asset accumulation

A few months ago, BioCentury spilled a lot of ink to deconstruct the NRDO model of no-research, development only companies being formed to scavenge for products or technologies that can be commercialized quickly and offer...
Items per page:
1 - 2 of 2